Home Medicine Real-time monitoring of drug laboratory test interactions: a proof of concept
Article
Licensed
Unlicensed Requires Authentication

Real-time monitoring of drug laboratory test interactions: a proof of concept

  • Jasmijn A. van Balveren EMAIL logo , Wilhelmine P.H.G. Verboeket-van de Venne , Carine J.M. Doggen , Lale Erdem-Eraslan , Albert J. de Graaf , Johannes G. Krabbe , Ruben E.A. Musson , Wytze P. Oosterhuis , Yolanda B. de Rijke , Heleen van der Sijs , Andrei N. Tintu , Rolf J. Verheul , Rein M.J. Hoedemakers and Ron Kusters
Published/Copyright: November 9, 2021

Abstract

Objectives

For the correct interpretation of test results, it is important to be aware of drug-laboratory test interactions (DLTIs). If DLTIs are not taken into account by clinicians, erroneous interpretation of test results may lead to a delayed or incorrect diagnosis, unnecessary diagnostic testing or therapy with possible harm for patients. A DLTI alert accompanying a laboratory test result could be a solution. The aim of this study was to test a multicentre proof of concept of an electronic clinical decision support system (CDSS) for real-time monitoring of DLTIs.

Methods

CDSS was implemented in three Dutch hospitals. So-called ‘clinical rules’ were programmed to alert medical specialists for possible DLTIs based on laboratory test results outside the reference range in combination with prescribed drugs. A selection of interactions from the DLTI database of the Dutch society of clinical chemistry and laboratory medicine were integrated in 43 clinical rules, including 24 tests and 25 drugs. During the period of one month all generated DTLI alerts were registered in the laboratory information system.

Results

Approximately 65 DLTI alerts per day were detected in each hospital. Most DLTI alerts were generated in patients from the internal medicine and intensive care departments. The most frequently reported DLTI alerts were potassium-proton pump inhibitors (16%), potassium-beta blockers (11%) and creatine kinase-statins (11%).

Conclusions

This study shows that it is possible to alert for potential DLTIs in real-time with a CDSS. The CDSS was successfully implemented in three hospitals. Further research must reveal its usefulness in clinical practice.


Corresponding author: Jasmijn A. van Balveren, MD, Laboratory for Clinical Chemistry and Haematology, Jeroen Bosch Hospital, Henri Dunantstraat 1, PO Box 90153, ’s-Hertogenbosch, The Netherlands; and Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands, Phone: +31 (0)73 553 27 64, Fax: +31 (0)73 5532958, LinkedIn: Jasmijn van Balveren, E-mail:

Funding source: Stichting Kwaliteitsgelden Medisch Specialisten (SKMS)

Award Identifier / Grant number: 42678870

Acknowledgments

We thank all IT specialists of the participating hospitals and Paul de Clercq (founder of Gaston Medical) for their effort in implementing the CDSS.

  1. Research funding: Funding from Stichting Kwaliteitsgelden Medisch Specialisten (SKMS), grant number 42678870.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Not applicable.

  5. Ethical approval: The local Institutional Review Board deemed the study exempt from review.

References

1. Young, D. Effects of drugs on clinical laboratory tests, 5th ed. Washington: AACC Press; 2000.Search in Google Scholar

2. Vroemen, WH, van Doorn, WP, Kimenai, DM, Wodzig, WK, de Boer, D, Bekers, O, et al.. Biotin interference in high-sensitivity cardiac troponin T testing: a real-world evaluation in acute cardiac care. Cardiovasc Res 2019;115:1950–1. https://doi.org/10.1093/cvr/cvz277.Search in Google Scholar

3. Yao, H, Rayburn, ER, Shi, Q, Gao, L, Hu, W, Li, H. Fda-approved drugs that interfere with laboratory tests: a systematic search of us drug labels. Crit Rev Clin Lab Sci 2016:1–17. https://doi.org/10.1080/10408363.2016.1191425.Search in Google Scholar

4. Vlasveld, LT, van ’t Wout, J, Castel, A. False elevation of chromogranin a due to proton pump inhibitors. Neth J Med 2011;69:207.Search in Google Scholar

5. Perera, NJ, Stewart, PM, Williams, PF, Chua, EL, Yue, DK, Twigg, SM. The danger of using inappropriate point-of-care glucose meters in patients on icodextrin dialysis. Diabet Med 2011;28:1272–6. https://doi.org/10.1111/j.1464-5491.2011.03362.x.Search in Google Scholar

6. Sunderman, FWJr. Drug interference in clinical biochemistry. CRC Crit Rev Clin Lab Sci 1970;1:427–49. https://doi.org/10.3109/10408367009027950.Search in Google Scholar

7. Wepler, R, Rommel, K. Drugs and parameters in the laboratory medicine. Dtsch Med Wochenschr 1973;98:2307–11. https://doi.org/10.1055/s-0028-1107247.Search in Google Scholar

8. Groves, WE, Gajewski, WH. Use of a clinical laboratory computer to warn of possible drug interference with test results. Comput Progr Biomed 1978;8:275–82. https://doi.org/10.1016/0010-468x(78)90035-1.Search in Google Scholar

9. van Balveren, JA. Clinical usefulness of drug-laboratory test interaction alerts: a multicentre survey. Clin Chem Lab Med 2021;59:1239–45. https://doi.org/10.1515/cclm-2020-1770.Search in Google Scholar PubMed

10. van Balveren, JA, Verboeket-van de Venne, W, Erdem-Eraslan, L, de Graaf, AJ, Loot, AE, Musson, REA, et al.. Impact of interactions between drugs and laboratory test results on diagnostic test interpretation – a systematic review. Clin Chem Lab Med 2018;56:2004–9. https://doi.org/10.1515/cclm-2018-0900.Search in Google Scholar PubMed

11. Werkgroep geneesmiddel-test interacties. Leidraad interactie klinisch-chemische parameters en geneesmiddelengebruik. Ned Tijdschr Klin Chem Lab 2017;42:37–49.Search in Google Scholar

12. Neubert, A, Dormann, H, Prokosch, HU, Burkle, T, Rascher, W, Sojer, R, et al.. E-pharmacovigilance: development and implementation of a computable knowledge base to identify adverse drug reactions. Br J Clin Pharmacol 2013;1:69–77. https://doi.org/10.1111/bcp.12127.Search in Google Scholar PubMed PubMed Central

13. Helmons, PJ, Suijkerbuijk, BO, Nannan Panday, PV, Kosterink, JG. Drug-drug interaction checking assisted by clinical decision support: a return on investment analysis. J Am Med Inf Assoc 2015;22:764–72. https://doi.org/10.1093/jamia/ocu010.Search in Google Scholar PubMed

14. de Clercq, PA, Blom, JA, Korsten, HH, Hasman, A. Approaches for creating computer-interpretable guidelines that facilitate decision support. Artif Intell Med 2004;31:1–27. https://doi.org/10.1016/j.artmed.2004.02.003.Search in Google Scholar

15. de Clercq, PA, Hasman, A, Blom, JA, Korsten, HH. Design and implementation of a framework to support the development of clinical guidelines. Int J Med Inform 2001;64:285–318. https://doi.org/10.1016/s1386-5056(01)00189-7.Search in Google Scholar

16. Kailajarvi, M, Takala, T, Gronroos, P, Tryding, N, Viikari, J, Irjala, K, et al.. Reminders of drug effects on laboratory test results. Clin Chem 2000;46:1395–400.10.1093/clinchem/46.9.1395Search in Google Scholar

17. van der Sijs, H, Aarts, J, Vulto, A, Berg, M. Overriding of drug safety alerts in computerized physician order entry. J Am Med Inf Assoc 2006;13:138–47. https://doi.org/10.1197/jamia.m1809.Search in Google Scholar PubMed PubMed Central

18. Bates, DW, Kuperman, GJ, Wang, S, Gandhi, T, Kittler, A, Volk, L, et al.. Ten commandments for effective clinical decision support: making the practice of evidence-based medicine a reality. J Am Med Inf Assoc 2003;10:523–30. https://doi.org/10.1197/jamia.m1370.Search in Google Scholar PubMed PubMed Central

19. Horsky, J, Aarts, J, Verheul, L, Seger, DL, van der Sijs, H, Bates, DW. Clinical reasoning in the context of active decision support during medication prescribing. Int J Med Inform 2017;97:1–11. https://doi.org/10.1016/j.ijmedinf.2016.09.004.Search in Google Scholar PubMed

20. Friedman, RB, Young, DS, Beatty, ES. Automated monitoring of drug-test interactions. Clin Pharmacol Ther 1978;24:16–21. https://doi.org/10.1002/cpt197824116.Search in Google Scholar PubMed

21. Rudolf, JW, Dighe, AS. Decision support tools within the electronic health record. Clin Lab Med 2019;39:197–213. https://doi.org/10.1016/j.cll.2019.01.001.Search in Google Scholar PubMed

22. Procop, GW, Weathers, AL, Reddy, AJ. Operational aspects of a clinical decision support program. Clin Lab Med 2019;39:215–29. https://doi.org/10.1016/j.cll.2019.01.002.Search in Google Scholar PubMed

Received: 2021-07-12
Accepted: 2021-10-28
Published Online: 2021-11-09
Published in Print: 2022-01-27

© 2021 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. The clinical value of assessing the inter-method bias: the lesson from prostate specific antigen measurement
  4. Mini Review
  5. Methods to reduce lipemic interference in clinical chemistry tests: a systematic review and recommendations
  6. Opinion Paper
  7. Troponin interference with special regard to macrocomplex formation
  8. Guidelines and Recommendations from Scientific Societies
  9. Use of high-sensitivity cardiac troponins in the emergency department for the early rule-in and rule-out of acute myocardial infarction without persistent ST-segment elevation (NSTEMI) in Italy
  10. Genetics and Molecular Diagnostics
  11. Effect of preexamination conditions in a centralized-testing model of non-invasive prenatal screening
  12. General Clinical Chemistry and Laboratory Medicine
  13. Comparative study of human growth hormone measurements: impact on clinical interpretation
  14. Establishing pre-analytical requirements and maximizing peptide recovery in the analytical phase for mass spectrometric quantification of amyloid-β peptides 1–42 and 1–40 in CSF
  15. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid
  16. Targeted profiling of 24 sulfated and non-sulfated bile acids in urine using two-dimensional isotope dilution UHPLC-MS/MS
  17. High-resolution capillary electrophoresis for the determination of carbamylated albumin
  18. Real-time monitoring of drug laboratory test interactions: a proof of concept
  19. Afamin predicts the prevalence and incidence of nonalcoholic fatty liver disease
  20. Reference Values and Biological Variations
  21. Blood sampling frequency as a proxy for comorbidity indices when identifying patient samples for review of reference intervals
  22. Coagulation parameters in the newborn and infant – the Copenhagen Baby Heart and COMPARE studies
  23. Hematology and Coagulation
  24. Policies and practices in the field of laboratory hematology in Croatia – a current overview and call for improvement
  25. Cardiovascular Diseases
  26. Evaluation of the Atellica TnIH cardiac troponin I assay and assessment of biological equivalence
  27. Infectious Diseases
  28. Inadequate design of mutation detection panels prevents interpretation of variants of concern: results of an external quality assessment for SARS-CoV-2 variant detection
  29. Letters to the Editors
  30. The pronounced decline of anti-SARS-CoV-2 spike trimeric IgG and RBD IgG in baseline seronegative individuals six months after BNT162b2 vaccination is consistent with the need for vaccine boosters
  31. ACE polymorphism is a determinant for COVID-19 mortality in the post-vaccination era
  32. A look at the precision, sensitivity and specificity of SARS-CoV-2 RT-PCR assays through a dedicated external quality assessment round
  33. Value of hypocalcemia and thromboinflammatory biomarkers for prediction of COVID-19 severity during the second wave: were all the waves the same?
  34. Metagenomic next-generation sequencing (mNGS) confirmed a critical case of severe fever with thrombocytopenia syndrome virus (SFTSV)
  35. Biotin interference: evaluation of an updated thyroglobulin electrochemiluminescent immunoassay
  36. Evaluation of the Beckman Coulter Access Procalcitonin Assay: analytical and clinical performance
  37. Analytical performance evaluation of the new sST2 turbidimetric assay implemented in laboratory automation systems
  38. Pre-analytical recommendations and reference values for circulating calprotectin are sample type and assay dependent
  39. Congress Abstracts
  40. Annual Meeting of the Royal Belgian Society of Laboratory Medicine: “Women’s health: from puberty to menopause”
Downloaded on 14.1.2026 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2021-0790/html
Scroll to top button